Volume 16, Number 7—July 2010
Vaccine-associated Paralytic Poliomyelitis in Immunodeficient Children, Iran, 1995–2008
||Age, mo/sex at VAPP onset
||OPV, no. doses
||Time intervals||Poliovirus type
||Viral protein 1 nt divergence,† %
|Last OPV and
||Virus shedding from VAPP onset
||VAPP onset and death
|1||17/F||0‡||0||1.2 mo||8 d||iVDPV type 2||2.2|
|2||7/M||4||1.1 mo||3 mo||4 mo||iVDPV type 2||1.1–1.5|
|3||10/M||4||3.3 mo||2 wk||1 mo||iVDPV type 2||1.7|
|4||15/M||4||9 mo||5 mo||11 mo||iVDPV type 3||2|
|5||5/F||2||3.2 mo||5 d||1 mo||iVDPV type 2, iVDPV type 1||Type 2: 1.7–2; type 1: 1.7|
|6||20/M||4||1.1 mo||3 d||NA§||iVDPV type 2||1.2|
*VAPP, vaccine-associated paralytic poliomyelitis; OPV, oral polio vaccine; iVDPV, immunodeficiency-associated vaccine-derived polioviruses.
†From the prototype Sabin strain.
‡Inactivated polio vaccine was administered. Contact case-patient of a healthy OPV-vaccinated sibling.
§Alive to date, has residual paralysis.
- Page created: March 02, 2011
- Page last updated: March 02, 2011
- Page last reviewed: March 02, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)